U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07447141) titled 'DBM-1152A Inhalation Solution in Chinese Healthy Subjects' on Feb. 01.
Brief Summary: This is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of DBM-1152A Inhalation Solution in healthy Chinese adult subjects.
Study Start Date: Dec. 24, 2023
Study Type: INTERVENTIONAL
Condition:
Health
Health Adult Subjects
Intervention:
DRUG: DBM-1152A Inhalation Solution
Single dose via oral inhalation nebulization.
DRUG: Placebo
Single dose of blank vehicle via oral inhalation ne...